Skip to main content
. Author manuscript; available in PMC: 2013 Sep 9.
Published in final edited form as: J Immunol. 2010 Sep 15;185(8):4750–4759. doi: 10.4049/jimmunol.1000769

FIGURE 7.

FIGURE 7

Survival of islet allografts with a combined treatment of TGF-β1/Fc and rapamycin. (A) Diabetic B6AF1 mice were transplanted with DBA/2 islets allograft under the renal capsule and treated with TGF-β1/Fc, or rapamycin, alone or in combination, as indicated in the Materials and Methods. The MST for the untreated recipients was 19 days and for the TGF-β1/Fc-treated recipients 61 days. Recipients treated with rapamycin exhibited prolonged islet graft survival (MST 85 days), whereas combined treatment led to indefinite survival of most (90%) of the islets allografts (MST > 120 days). (B) Second islet transplantation. Three recipients bearing long-surviving islet allografts were nephrectomized to remove their grafts 150 days after transplantation. Two nephrectomized mice received a second DBA/2 islet allograft under the contralateral renal capsule without further immunosuppression and accepted the second transplant for > 100 days. One mouse received a third party (C3H) islet allograft which was rejected at day 11.